arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

Dermata Therapeutics, Inc.

DRMA

$1.10 ▼ -0.01 (-0.90%) at close

26 Visible periods

18 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Dermata Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.2M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -23.7% →

FCF / Share $-0.64

Trailing P/E —

Price / Book 0.7x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

26-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-1.85M

↑ +19.8% —

FCF / Share Free cash flow per share

$-0.64

↓ -71.3% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Dec 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Dec 31, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗
EPS Growth YoY (%)	-6.7% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	N/M	91.9% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	96.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	N/M	-3679.6% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-6538.1% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	-1814.8% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	—	83.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-587.9% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	72.7% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—	—	—
Net Income Growth YoY (%)	19.8% Good ↓ Good Declining Year-over-year change in net income	40.9% Excellent ↑ Excellent Improving Year-over-year change in net income	26.5% Excellent ↑ Excellent Improving Year-over-year change in net income	26.5% Excellent ↑ Excellent Improving Year-over-year change in net income	26.5% Excellent ↑ Excellent Improving Year-over-year change in net income	-47.7% Weak ↓ Weak Declining Year-over-year change in net income	-39.9% Weak ↓ Weak Declining Year-over-year change in net income	-39.9% Weak ↓ Weak Declining Year-over-year change in net income	-39.9% Weak ↓ Weak Declining Year-over-year change in net income	-27.8% Weak ↓ Weak Declining Year-over-year change in net income	19.6% Good ↓ Good Declining Year-over-year change in net income	19.6% Good ↑ Good Improving Year-over-year change in net income	19.6% Good ↑ Good Improving Year-over-year change in net income	34.6% Excellent ↑ Excellent Improving Year-over-year change in net income	-20.9% Weak ↑ Weak Improving Year-over-year change in net income	-20.9% Weak ↑ Weak Improving Year-over-year change in net income	-20.9% Weak ↑ Weak Improving Year-over-year change in net income	-544.2% Weak ↓ Weak Declining Year-over-year change in net income	-62.2% Weak Weak Year-over-year change in net income	-62.2% Weak Weak Year-over-year change in net income	—	—	—	—	—	—
FCF Growth YoY (%)	-71.3% Weak Weak Year-over-year change in free cash flow	—	92.0% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—	—	—	—	—	23.1% Good Good Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Dec 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Dec 31, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗
FCF / Net Income (x)	1.34x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.71x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.78x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.17x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.84x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	1.09x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.68x Weak → Weak Stable Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.54x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	0.74x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.09x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	—	0.66x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.71x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	0.34x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	18.98x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	-3.95x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Dec 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Dec 31, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-23.7% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-24.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-35.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-24.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-25.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-162.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-53.7% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-68.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-66.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-27.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-22.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-17.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-22.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-22.5% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-25.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-22.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-28.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-20.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-10.8% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	207.7% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-251.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	12.2% Good ↓ Good Declining Return earned on debt + equity capital invested Optimal: > 10%	15.3% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	28.4% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-25.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-24.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-34.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-26.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-23.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	-90.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	-61.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-27.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-24.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-19.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-24.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-24.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-27.3% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	—	-30.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-22.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-12.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-117.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	-81.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	-28.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-292%)	-29.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-299%)	-58.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-488%)	-41.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-374%)	-31.6% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-310%)	-201.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1446%)	-66.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-541%)	-94.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-730%)	-82.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-649%)	-33.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-324%)	-35.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-333%)	-27.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-286%)	-27.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-285%)	-27.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-285%)	-37.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-349%)	-28.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-292%)	-35.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-337%)	-25.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-268%)	-18.5% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-223%)	—	—	12.5% Fair ↓ Fair Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-17%)	51.1% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+241%)	64.5% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+330%)	—	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Dec 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Dec 31, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗
Interest Coverage (x)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-113.84x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	-2630.21x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-729.55x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-52.43x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-12.77x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-9.42x Weak Weak Operating income divided by interest expense Optimal: > 5x	-27.47x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—
Net Debt (USD)	$-6.95M	$-7.52M	$-4.66M	$-6.48M	$-9.72M	$-3.16M	—	—	—	—	$-6.63M	$-8.44M	$-8.77M	—	$-8.07M	—	$-8.19M	$-10.80M	$-12.60M	$-427.20K	—	$-530.40K	—	—	—	—

📊 What does each share earn? 5 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Dec 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Dec 31, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗
Basic EPS, GAAP (USD)	$-0.48	$-1.52	$-1.65	$-1.66	$-0.45	$21.86	$-20.41	$-41.82	—	$-37.53	$-0.54	$-0.63	$-2.27	$-1.96	—	$-3.90	$-0.33	—	—	—	$-1.21	—	—	—	—	—
Free Cash Flow per Share (USD)	$-0.64	—	$-1.76	$-2.62	$-0.38	—	$-21.99	—	—	—	—	—	—	—	—	—	$-0.31	—	—	—	$-0.41	—	—	—	—	—
Book Value per Share (USD)	$1.59	$2.34	$4.69	$8.80	$1.21	$6.20	$30.50	—	$0.57	$24.26	$2.01	$2.52	$3.39	$7.82	$0.62	—	$0.94	$1.21	$1.50	$-0.26	$0.37	—	—	—	—	—
Tangible Book Value per Share (USD)	$1.59	$2.34	$4.69	$8.80	$1.21	$6.20	$30.50	—	$0.57	$24.26	$2.01	$2.52	$3.39	$7.82	$0.62	—	$0.94	$1.21	$1.50	$-0.26	$0.37	—	—	—	—	—
Basic Weighted Avg Shares (shares)	3.86M	—	1.03M	1.03M	5.15M	—	155,465	67,654	—	—	—	—	—	—	—	—	8.35M	—	—	—	1.91M	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Dec 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Dec 31, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	$12.49M	$-505.80K	—	$-3.18M	—	—	—	—
Total Equity (USD)	$6.41M	$6.22M	$3.96M	$5.61M	$7.30M	$1.56M	$4.74M	$3.32M	$3.81M	$6.36M	$6.41M	$8.03M	$8.09M	$6.02M	$7.47M	$9.66M	$7.85M	$10.11M	$12.49M	$-505.80K	$712.00K	$-3.18M	$-2.78M	$-2.20M	$-1.63M	$-210.16K

📋 What is driving earnings? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Dec 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Dec 31, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗
Net Income, GAAP (USD)	$-1.85M	$-1.86M	$-2.30M	$-2.30M	$-2.30M	$-3.15M	$-3.13M	$-3.13M	$-3.13M	$-2.13M	$-2.24M	$-2.24M	$-2.24M	$-1.67M	$-2.79M	$-2.79M	$-2.79M	$-2.55M	$-2.30M	$-2.30M	$-2.30M	$-396.31K	$-1.42M	$-1.42M	—	—
Operating Cash Flow (USD)	$-2.48M	$-1.33M	$-1.80M	$-2.69M	$-1.93M	$-2.91M	$-3.42M	$-2.13M	$-2.70M	$-1.15M	—	—	$-1.65M	$-1.83M	—	$-1.84M	$-2.61M	$-1.80M	—	—	$-776.22K	$-7.52M	$5.62M	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters

Dermata Therapeutics, Inc.

Analytical Summary

26-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare DRMA with peers